Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-20 of 97 (Search time: 0.002 seconds).
previous
1
2
3
4
5
...
10
next
Item hits:
Preview
Issue Date
Title
Author(s)
2014
The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Parker, W.
;
Braley, J.
;
Seymour, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2017
Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia
Sopper, S.
;
Mustjoki, S.
;
White, D.
;
Hughes, T.
;
Valent, P.
;
Burchert, A.
;
Gjertsen, B.
;
Gastl, G.
;
Baldauf, M.
;
Trajanoski, Z.
;
Giles, F.
;
Hochhaus, A.
;
Ernst, T.
;
Schenk, T.
;
Janssen, J.
;
Ossenkoppele, G.
;
Porkka, K.
;
Wolf, D.
2013
PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations
Parker, W.
;
Phillis, S.
;
Yeung, D.
;
Hughes, T.
;
Scott, H.
;
Branford, S.
;
55th American Society of Hematology Annual Meeting and Exhibition (7 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
2014
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, T.
;
Saglio, G.
;
Kantarjian, H.
;
Guilhot, F.
;
Niederwieser, D.
;
Rosti, G.
;
Nakaseko, C.
;
De Souza, C.
;
Kalaycio, M.
;
Meier, S.
;
Fan, X.
;
Menssen, H.
;
Larson, R.
;
Hochhaus, A.
2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Branford, S.
;
Yeung, D.
;
Parker, W.
;
Roberts, N.
;
Purins, L.
;
Braley, J.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Donaldson, Z.
;
Leong, M.
;
Fletcher, L.
;
Seymour, J.
;
Grigg, A.
;
Ross, D.
;
Hughes, T.
2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination
Parker, W.
;
Phillis, S.
;
Yeung, D.
;
Hughes, T.
;
Scott, H.
;
Branford, S.
2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
Hughes, T.
;
Lipton, J.
;
Spector, N.
;
Cervantes, F.
;
Pasquini, R.
;
Clementino, N.
;
Dorlhiac Llacer, P.
;
Schwarer, A.
;
Mahon, F.
;
Rea, D.
;
Branford, S.
;
Purkayastha, D.
;
Collins, L.
;
Szczudlo, T.
;
Leber, B.
2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Ross, D.
;
Pagani, I.
;
Shanmuganathan, N.
;
Kok, C.
;
Seymour, J.
;
Mills, A.
;
Filshie, R.
;
Arthur, C.
;
Dang, P.
;
Saunders, V.
;
Braley, J.
;
Yong, A.
;
Yeung, D.
;
White, D.
;
Grigg, A.
;
Schwarer, A.
;
Branford, S.
;
Hughes, T.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Olshen, A.
;
Tang, M.
;
Cortes, J.
;
Gonen, M.
;
Hughes, T.
;
Branford, S.
;
Quintás-Cardama, A.
;
Michor, F.
Discover
Author
41
White, D.
35
Branford, S.
20
Hochhaus, A.
19
Yeung, D.
17
Kantarjian, H.
17
Saglio, G.
15
Kim, D.
15
Ross, D.
13
Radich, J.
12
Larson, R.
.
next >
Subject
45
Humans
38
Pyrimidines
36
Leukemia, Myelogenous, Chronic, B...
31
Piperazines
30
Benzamides
28
Antineoplastic Agents
28
Imatinib Mesylate
27
Protein Kinase Inhibitors
20
Fusion Proteins, bcr-abl
14
Female
.
next >
Date issued
6
2018
7
2017
6
2016
3
2015
11
2014
19
2013
12
2012
11
2011
22
2010